Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
To explore the overall response rate (ORR) per RECIST 1.1 as assessed by investigators in
subjects with refractory small cell lung cancer treated with pembrolizumab (Pembro) plus
amurubicin (AMR).